These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11552909)

  • 21. Effect of cisapride on postprandial gastro-oesophageal reflux.
    Holloway RH; Downton J; Mitchell B; Dent J
    Gut; 1989 Sep; 30(9):1187-93. PubMed ID: 2680794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of motilin agonist ABT-229 on gastro-oesophageal reflux, oesophageal motility and lower oesophageal sphincter characteristics in GERD patients.
    Van Herwaarden MA; Samsom M; Van Nispen CH; Verlinden M; Smout AJ
    Aliment Pharmacol Ther; 2000 Apr; 14(4):453-62. PubMed ID: 10759625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nizatidine and cisapride enhance salivary secretion in humans.
    Adachi K; Ono M; Kawamura A; Yuki M; Fujishiro H; Kinoshita Y
    Aliment Pharmacol Ther; 2002 Feb; 16(2):297-301. PubMed ID: 11860413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prokinetics and reflux: a promise unfulfilled.
    de Caestecker J
    Eur J Gastroenterol Hepatol; 2002 Jan; 14(1):5-7. PubMed ID: 11782568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux.
    Poynard T; Vernisse B; Agostini H
    Aliment Pharmacol Ther; 1998 Feb; 12(2):159-65. PubMed ID: 9692690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of cisapride on food-stimulated gastro-oesophageal reflux: a radiological study.
    Gelineck J; Aksglade K; Funch-Jensen P; Thommesen P
    Rontgenblatter; 1990 Aug; 43(8):352-4. PubMed ID: 2204995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical use of cisapride in gastro-oesophageal reflux disease, with particular focus on the long-term treatment aspects.
    Tytgat GN
    Scand J Gastroenterol Suppl; 1995; 211():39-43. PubMed ID: 8545630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of cisapride on oesophageal motility and duodenogastro-oesophageal reflux in patients with Barrett's oesophagus.
    Smythe A; Bird NC; Troy GP; Globe J; Johnson AG
    Eur J Gastroenterol Hepatol; 1997 Dec; 9(12):1149-53. PubMed ID: 9471019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cisapride treatment for children with gastro-esophageal reflux].
    Kneepkens CM; Hoekstra JH; Vandenplas Y
    Ned Tijdschr Geneeskd; 1999 Oct; 143(42):2091-4. PubMed ID: 10560558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
    Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
    Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cisapride for gastro-oesophageal reflux and peptic oesophagitis.
    Cucchiara S; Staiano A; Capozzi C; Di Lorenzo C; Boccieri A; Auricchio S
    Arch Dis Child; 1987 May; 62(5):454-7. PubMed ID: 3300570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost effectiveness of treatment for gastro-oesophageal reflux.
    Laheij RJ; Jansen JB; Severens JL; Verbeek AL
    Gut; 1998 Nov; 43(5):728-9; author reply 729-30. PubMed ID: 9917194
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease.
    Hatlebakk JG; Johnsson F; Vilien M; Carling L; Wetterhus S; Thøgersen T
    Scand J Gastroenterol; 1997 Nov; 32(11):1100-6. PubMed ID: 9399390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease.
    Simon B; Müller P; Pascu O; Gatz G; Sander P; Huber R; Mascher H
    Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):791-9. PubMed ID: 12811310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of salivation and heartburn in response to the site of acid infusion in the human oesophagus.
    Dutta SK; Agrawal K; Mahmoud MA
    Aliment Pharmacol Ther; 2010 Sep; 32(6):795-800. PubMed ID: 20629975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease.
    Ruth M; Hamelin B; Röhss K; Lundell L
    Aliment Pharmacol Ther; 1998 Jan; 12(1):35-40. PubMed ID: 9692698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastro-oesophageal reflux and chronic respiratory disease in infants and children: treatment with cisapride.
    Olafsdottir E
    Scand J Gastroenterol Suppl; 1995; 211():32-4. PubMed ID: 8545628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cisapride: influence on oesophageal and gastric emptying and gastro-oesophageal reflux in patients with reflux oesophagitis.
    Collins BJ; Spence RA; Ferguson R; Laird J; Love AH
    Hepatogastroenterology; 1987 Jun; 34(3):113-6. PubMed ID: 3301606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Are prokinetic drugs still indicated for gastro-oesophageal reflux in children?].
    Dupont C; Benhamou PH
    Arch Pediatr; 2004 Jun; 11(6):671-3. PubMed ID: 15158877
    [No Abstract]   [Full Text] [Related]  

  • 40. The diagnosis and treatment of gastro-oesophageal reflux disease in infants and children.
    Vandenplas Y
    Ann Med; 1993 Aug; 25(4):323-8. PubMed ID: 8217096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.